As filed with the Securities and Exchange Commission on March 18, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
VIRACTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 94-3295878 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification Number) |
2533 S Coast Hwy 101, Suite 210
Cardiff, California 92007
(858) 400-8470
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2021 Equity Incentive Plan
2021 Inducement Equity Incentive Plan
(Full title of the plan)
Ivor Royston, M.D.
President and Chief Executive Officer
Viracta Therapeutics, Inc.
2533 S Coast Hwy 101, Suite 210
Cardiff, California 92007
(858) 400-8470
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| | |
Martin J. Waters Wilson Sonsini Goodrich & Rosati Professional Corporation 12235 El Camino Real San Diego, CA 92130 (858) 350-2300 | | Daniel Chevallard Chief Operating Officer and Chief Financial Officer Viracta Therapeutics, Inc. 2533 S Coast Hwy 101, Suite 210 Cardiff, California 92007 (858) 400-8470 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐